<p>The government may allow emergency use of Covid-19 vaccine in two weeks, paving way for a much-awaited nationwide immunisation programme, according to report by <a href="https://www.livemint.com/news/india/emergency-vaccine-nod-likely-in-2-weeks-11607386523226.html" target="_blank"><em>Mint</em></a>, quoting sources in the Health Ministry.</p>.<p>The officials of the Drug Controller General of India (DCGI) said that a subject expert panel of Central Drugs Standards Control Organisation is scheduled to meet this week to decide the most suitable vaccine candidate for rollout. </p>.<p>On Tuesday, the UK became the first western country to rollout mass vaccination against the novel coronavirus. </p>.<p><strong><a href="https://www.deccanherald.com/coronavirus-live-news-covid-19-latest-updates.html" target="_blank">CORONAVIRUS SPECIAL COVERAGE ONLY ON DH</a></strong></p>.<p>India is currently fast-tracking vaccine approval to curb the spread of the coronavirus, which has killed over 1.4 lakh people, making the nation the worst affected after the United States.</p>.<p>Pfizer was the first firm to approach DCGI for emergency use approval for its messenger-RNA vaccine that has produced robust efficacy against the virus in its US trials. </p>.<p>Adar Poonawalla-led Serum Institute of India on Sunday approached DCGI for emergency use nod for Astrazeneca Covid-19 vaccine. In addition, on Monday, Bharat Biotech also applied for approval for its vaccine, Covaxin.</p>.<p>“We will have a meeting this week to review the proposals of the vaccine manufacturers. A group of scientists and experts will make a summary and submit it to the higher authorities for further review," said a senior official at the CDSCO.</p>.<p>“All the safety issues will be considered before giving emergency authorization. The public wants a safe and effective vaccine for Covid-19 and for gaining public confidence, we need to be very careful before taking any decision," the official said.</p>.<p>Meanwhile, a <a href="https://www.hindustantimes.com/health/india-to-look-at-full-dose-data-of-oxford-vaccine/story-laVSz5q3Z8L3iZ3oEPiioM.html" target="_blank">report </a>by the <em>Hindustan Times </em>stated that the clinical trials of the Oxford-AstraZeneca vaccine will be based on two full doses and a result is expected within two weeks. The vaccine has shown 62 per cent efficacy for two full dose trials and 90 per cent efficacy when the first shot was half-strength dose, followed by a full dose at least one month apart.</p>
<p>The government may allow emergency use of Covid-19 vaccine in two weeks, paving way for a much-awaited nationwide immunisation programme, according to report by <a href="https://www.livemint.com/news/india/emergency-vaccine-nod-likely-in-2-weeks-11607386523226.html" target="_blank"><em>Mint</em></a>, quoting sources in the Health Ministry.</p>.<p>The officials of the Drug Controller General of India (DCGI) said that a subject expert panel of Central Drugs Standards Control Organisation is scheduled to meet this week to decide the most suitable vaccine candidate for rollout. </p>.<p>On Tuesday, the UK became the first western country to rollout mass vaccination against the novel coronavirus. </p>.<p><strong><a href="https://www.deccanherald.com/coronavirus-live-news-covid-19-latest-updates.html" target="_blank">CORONAVIRUS SPECIAL COVERAGE ONLY ON DH</a></strong></p>.<p>India is currently fast-tracking vaccine approval to curb the spread of the coronavirus, which has killed over 1.4 lakh people, making the nation the worst affected after the United States.</p>.<p>Pfizer was the first firm to approach DCGI for emergency use approval for its messenger-RNA vaccine that has produced robust efficacy against the virus in its US trials. </p>.<p>Adar Poonawalla-led Serum Institute of India on Sunday approached DCGI for emergency use nod for Astrazeneca Covid-19 vaccine. In addition, on Monday, Bharat Biotech also applied for approval for its vaccine, Covaxin.</p>.<p>“We will have a meeting this week to review the proposals of the vaccine manufacturers. A group of scientists and experts will make a summary and submit it to the higher authorities for further review," said a senior official at the CDSCO.</p>.<p>“All the safety issues will be considered before giving emergency authorization. The public wants a safe and effective vaccine for Covid-19 and for gaining public confidence, we need to be very careful before taking any decision," the official said.</p>.<p>Meanwhile, a <a href="https://www.hindustantimes.com/health/india-to-look-at-full-dose-data-of-oxford-vaccine/story-laVSz5q3Z8L3iZ3oEPiioM.html" target="_blank">report </a>by the <em>Hindustan Times </em>stated that the clinical trials of the Oxford-AstraZeneca vaccine will be based on two full doses and a result is expected within two weeks. The vaccine has shown 62 per cent efficacy for two full dose trials and 90 per cent efficacy when the first shot was half-strength dose, followed by a full dose at least one month apart.</p>
